942437-37-8

Basic information

• Product Name: 3-CinnolinecarboxaMide, 4-aMino-8-(2-fluoro-6-Methoxyphenyl)-N-propyl-
• Synonyms: 3-CinnolinecarboxaMide, 4-aMino-8-(2-fluoro-6-Methoxyphenyl)-N-propyl-;AZD-7325
• CAS NO: 942437-37-8
• Molecular Formula: C19H19FN4O2
• Molecular Weight: 354.3781632
• EINECS: -0
• Product Categories: API
• Mol File: 942437-37-8.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-CinnolinecarboxaMide, 4-aMino-8-(2-fluoro-6-Methoxyphenyl)-N-propyl-(CAS DataBase Reference)
• NIST Chemistry Reference: 3-CinnolinecarboxaMide, 4-aMino-8-(2-fluoro-6-Methoxyphenyl)-N-propyl-(942437-37-8)
• EPA Substance Registry System: 3-CinnolinecarboxaMide, 4-aMino-8-(2-fluoro-6-Methoxyphenyl)-N-propyl-(942437-37-8)

Safety Data

• Hazardous Substances Data: 942437-37-8(Hazardous Substances Data)

Usage

General Description

3-Cinnolinecarboxamide, 4-amino-8-(2-fluoro-6-methoxyphenyl)-N-propyl- is a chemical compound with a cinnolinecarboxamide backbone and an amino group attached to the 4th position, as well as a propyl group attached to the 8th position. Additionally, there is a fluoro group at the 2nd position and a methoxy group at the 6th position of the phenyl group. 3-Cinnolinecarboxamide, 4-amino-8-(2-fluoro-6-methoxyphenyl)-N-propyl- may have potential applications in pharmaceutical research and development due to its unique structure and potential biological activity. It could be further studied for its potential in drug design and discovery, as well as in understanding structure-activity relationships in medicinal chemistry.

Upstream product

• 52493-35-3 2-cyano-N-propylacetamide 
• 1253049-53-4 (E)-N-propyl-2-cyano-2-[(2-bromophenyl)hydrazono]acetamide 
• 107346-32-7 4-amino-8-bromo-N-propyl-cinnoline-3-carboxamide 
• 7440-44-0 pyrographite 
• 78495-63-3 (2-fluoro-6-methoxyphenyl)boronic acid 

Relevant articles and documents

Development and SAR of functionally selective allosteric modulators of GABAA receptors

Positive modulators at the benzodiazepine site of α2- and α3-containing GABAA receptors are believed to be anxiolytic. Through oocyte voltage clamp studies, we have discovered two series of compounds that are positive modulators at α2-/α3-containing GABAA receptors and that show no functional activity at α1-containing GABA A receptors. We report studies to improve this functional selectivity and ultimately deliver clinical candidates. The functional SAR of cinnolines and quinolines that are positive allosteric modulators of the α2- and α3-containing GABAA receptors, while simultaneously neutral antagonists at α1-containing GABAA receptors, is described. Such functionally selective modulators of GABAA receptors are expected to be useful in the treatment of anxiety and other psychiatric illnesses.

Compounds and Uses Thereof

This invention relates to novel compounds having the structural formula I below: and their pharmaceutically acceptable salts, tautomers or in vivo-hydrolysable precursors, compositions and methods of use thereof. These novel compounds provide a treatment or prophylaxis of anxiety disorders, cognitive disorders, and/or mood disorders.